ABIGAIL SUZANNE CAUDLE to Humans
This is a "connection" page, showing publications ABIGAIL SUZANNE CAUDLE has written about Humans.
Connection Strength
0.505
-
Evidence-Based Strategies to Minimize the Likelihood of Axillary Lymph Node Dissection in Clinically Node-Positive Patients Following Neoadjuvant Chemotherapy. Surg Oncol Clin N Am. 2023 10; 32(4):693-703.
Score: 0.018
-
Invited Commentary: De-escalation of axillary surgery in node-positive breast cancer patients after neoadjuvant therapy. Surgery. 2023 08; 174(2):419-421.
Score: 0.018
-
Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients. Ann Surg Oncol. 2021 Aug; 28(8):4277-4283.
Score: 0.015
-
Sentinel Node Lymph Node Surgery After Neoadjuvant Therapy: Principles and Techniques. Ann Surg Oncol. 2019 Oct; 26(10):3040-3045.
Score: 0.014
-
Do Internal Mammary Nodes Matter? Ann Surg Oncol. 2019 Apr; 26(4):930-932.
Score: 0.013
-
Feasibility of fine-needle aspiration for assessing responses to chemotherapy in metastatic nodes marked with clips in breast cancer: A prospective registry study. Cancer. 2019 02 01; 125(3):365-373.
Score: 0.013
-
Intraoperative Pathologic Evaluation with Targeted Axillary Dissection : Editorial for "Intraoperative Touch Imprint Cytology in Targeted Axillary Dissection After Neoadjuvant Chemotherapy Among Breast Cancer Patients with Initial Axillary Metastasis". Ann Surg Oncol. 2018 Oct; 25(11):3112-3114.
Score: 0.013
-
Management of the Axilla in the?Patient with Breast Cancer. Surg Clin North Am. 2018 Aug; 98(4):747-760.
Score: 0.013
-
Expanding Implementation of ACOSOG Z0011 in Surgeon Practice. Clin Breast Cancer. 2018 08; 18(4):276-281.
Score: 0.012
-
Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members. Ann Surg Oncol. 2017 Oct; 24(10):2925-2934.
Score: 0.012
-
Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer. Ann Surg Oncol. 2016 10; 23(11):3501-3509.
Score: 0.011
-
Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol. 2016 Apr 01; 34(10):1072-8.
Score: 0.011
-
The Impact of Postoperative Complications on a Timely Return to Intended Oncologic Therapy (RIOT): the Role of Enhanced Recovery in the Cancer Journey. Int Anesthesiol Clin. 2016; 54(4):e33-46.
Score: 0.011
-
Targeting and limiting surgery for patients with node-positive breast cancer. BMC Med. 2015 Jun 25; 13:149.
Score: 0.010
-
Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. JAMA Surg. 2015 Feb; 150(2):137-43.
Score: 0.010
-
Less remains better: morbidity after axillary surgery. Ann Surg Oncol. 2015 Jan; 22(1):4-6.
Score: 0.010
-
Predicting the extent of nodal disease in early-stage breast cancer. Ann Surg Oncol. 2014 Oct; 21(11):3440-7.
Score: 0.010
-
Management of axillary disease. Surg Oncol Clin N Am. 2014 Jul; 23(3):473-86.
Score: 0.010
-
Breast conservation therapy after neoadjuvant chemotherapy: optimization of a multimodality approach. J Surg Oncol. 2014 Jul; 110(1):32-6.
Score: 0.010
-
Impact of identification of internal mammary sentinel lymph node metastasis in breast cancer patients. Ann Surg Oncol. 2014 Jan; 21(1):60-5.
Score: 0.009
-
American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol. 2012 Oct; 19(10):3144-51.
Score: 0.009
-
Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res. 2012 May 23; 14(3):R83.
Score: 0.008
-
Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol. 2011 Sep; 18(9):2407-12.
Score: 0.008
-
Response to the letter to the editor: Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: a practice-changing trial. Ann Surg Oncol. 2011 Dec; 18 Suppl 3:S283.
Score: 0.008
-
Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol. 2011 Apr; 18(4):932-8.
Score: 0.008
-
The neoadjuvant approach in breast cancer treatment: it is not just about chemotherapy anymore. Curr Opin Obstet Gynecol. 2011 Feb; 23(1):31-6.
Score: 0.008
-
Metastasectomy for stage IV melanoma: for whom and how much? Surg Oncol Clin N Am. 2011 Jan; 20(1):133-44.
Score: 0.008
-
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010 Apr 10; 28(11):1821-8.
Score: 0.007
-
Complications associated with neoadjuvant radiotherapy in the multidisciplinary treatment of retroperitoneal sarcomas. Ann Surg Oncol. 2007 Feb; 14(2):577-82.
Score: 0.006
-
Experienced radio-guided surgery teams can successfully perform minimally invasive radio-guided parathyroidectomy without intraoperative parathyroid hormone assays. Am Surg. 2006 Sep; 72(9):785-9; discussion 790.
Score: 0.006
-
Surgical management of distant metastases. Surg Oncol Clin N Am. 2006 Apr; 15(2):385-98.
Score: 0.005
-
Evaluation of traditional targeted axillary dissection eligibility criteria for node-positive breast cancer after neoadjuvant chemotherapy in a prospective multicenter registry. Eur J Surg Oncol. 2024 Apr; 50(4):108245.
Score: 0.005
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.
Score: 0.005
-
Racial and Ethnic Differences in Long-Term Adverse Radiation Therapy Effects Among Breast Cancer Survivors. Int J Radiat Oncol Biol Phys. 2024 Mar 01; 118(3):626-631.
Score: 0.005
-
To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer? Ann Surg Oncol. 2023 Dec; 30(13):8327-8334.
Score: 0.005
-
Patient-reported Quality of Life After Breast-conserving Surgery With Radiotherapy Versus Mastectomy and Reconstruction. Ann Surg. 2023 11 01; 278(5):e1096-e1102.
Score: 0.005
-
Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Sci Adv. 2023 02 03; 9(5):eadd6995.
Score: 0.004
-
Long-term Quality of Life in Patients With Breast Cancer After Breast Conservation vs Mastectomy and Reconstruction. JAMA Surg. 2022 06 01; 157(6):e220631.
Score: 0.004
-
Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2021 Oct; 28(10):5477-5485.
Score: 0.004
-
Surgical Outcomes in Cancer Patients Undergoing Elective Surgery After Recovering from Mild-to-Moderate SARS-CoV-2 Infection. Ann Surg Oncol. 2021 Dec; 28(13):8046-8053.
Score: 0.004
-
Acceptability of 3D-printed breast models and their impact on the decisional conflict of breast cancer patients: A feasibility study. J Surg Oncol. 2021 Apr; 123(5):1206-1214.
Score: 0.004
-
Anatomy and physiology of the sentinel lymph nodes of the upper extremity: Implications for axillary reverse mapping in breast cancer. J Surg Oncol. 2021 Mar; 123(4):846-853.
Score: 0.004
-
A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. Oncologist. 2021 02; 26(2):e230-e240.
Score: 0.004
-
Impact of SSO-ASTRO "No Ink on Tumor" Guidelines on Reexcision Rates among Older Breast Cancer Patients. Ann Surg Oncol. 2021 Jul; 28(7):3703-3713.
Score: 0.004
-
Complications of Contralateral Prophylactic Mastectomy: Do They Delay Adjuvant Therapy? Plast Reconstr Surg. 2020 11; 146(5):945-953.
Score: 0.004
-
Cancer Surgery Scheduling During and After the COVID-19 First Wave: The MD Anderson Cancer Center Experience. Ann Surg. 2020 08; 272(2):e106-e111.
Score: 0.004
-
Performance and Clinical Utility of Models Predicting Eradication of Nodal Disease in Patients with Clinically Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy by Tumor Biology. Ann Surg Oncol. 2020 Nov; 27(12):4678-4686.
Score: 0.004
-
Outcomes of Volume Replacement Oncoplastic Breast-Conserving Surgery Using Chest Wall Perforator Flaps: Comparison with Volume Displacement Oncoplastic Surgery and Total Breast Reconstruction. Plast Reconstr Surg. 2020 07; 146(1):14-27.
Score: 0.004
-
Immediate Contralateral Mastopexy/Breast Reduction for Symmetry Can Be Performed Safely in Oncoplastic Breast-Conserving Surgery. Plast Reconstr Surg. 2020 05; 145(5):1134-1142.
Score: 0.004
-
Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). J Clin Oncol. 2020 04 20; 38(12):1284-1292.
Score: 0.004
-
Opioid Use after Breast-Conserving Surgery: Prospective Evaluation of Risk Factors for High Opioid Use. Ann Surg Oncol. 2020 Mar; 27(3):730-735.
Score: 0.004
-
Facilitation of Surgical Innovation: Is It Possible to Speed the Introduction of New Technology While Simultaneously Improving Patient Safety? Ann Surg. 2019 12; 270(6):937-941.
Score: 0.004
-
Challenges in Clinical Trial Implementation: Results from a Survey of the National Accreditation Program of Breast Centers (NAPBC). Ann Surg Oncol. 2019 Dec; 26(13):4364-4371.
Score: 0.004
-
Sonographic features of benign and malignant axillary nodes post-neoadjuvant chemotherapy. Breast J. 2020 02; 26(2):182-187.
Score: 0.003
-
The role of three-dimensional printing in the surgical management of breast cancer. J Surg Oncol. 2019 Nov; 120(6):897-902.
Score: 0.003
-
Postoperative Urinary Tract Infection Quality Assessment and Improvement: The S.T.O.P. UTI Program and Its Impact on Hospitalwide CAUTI Rates. Jt Comm J Qual Patient Saf. 2019 10; 45(10):686-693.
Score: 0.003
-
Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019 07; 20(7):835-851.
Score: 0.003
-
Neoadjuvant Chemotherapy does not Increase Complications in Oncoplastic Breast-Conserving Surgery. Ann Surg Oncol. 2019 Sep; 26(9):2730-2737.
Score: 0.003
-
Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes. Breast Cancer Res Treat. 2019 Jul; 176(2):435-444.
Score: 0.003
-
Surgeon perception versus reality: Opioid use after breast cancer surgery. J Surg Oncol. 2019 Jun; 119(7):909-915.
Score: 0.003
-
Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy. Int J Radiat Oncol Biol Phys. 2018 11 01; 102(3):568-577.
Score: 0.003
-
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 05; 267(5):946-951.
Score: 0.003
-
Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. 2017 07 01; 152(7):665-670.
Score: 0.003
-
Molecular Profiling Using Breast Cancer Subtype to Plan for Breast Reconstruction. Plast Reconstr Surg. 2017 Mar; 139(3):586e-596e.
Score: 0.003
-
Radiologic Mapping for Targeted Axillary Dissection: Needle Biopsy to Excision. AJR Am J Roentgenol. 2016 Dec; 207(6):1372-1379.
Score: 0.003
-
Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. Ann Surg Oncol. 2017 Mar; 24(3):652-659.
Score: 0.003
-
Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. Int J Radiat Oncol Biol Phys. 2016 11 01; 96(3):637-44.
Score: 0.003
-
Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction. Ann Surg Oncol. 2016 10; 23(10):3190-8.
Score: 0.003
-
Trends in Local Therapy Utilization and Cost for Early-Stage Breast Cancer in Older Women: Implications for Payment and Policy Reform. Int J Radiat Oncol Biol Phys. 2016 06 01; 95(2):605-16.
Score: 0.003
-
Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. Ann Surg Oncol. 2016 May; 23(5):1515-21.
Score: 0.003
-
Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy. Ann Surg Oncol. 2016 Mar; 23(3):749-56.
Score: 0.003
-
Microcalcifications in 1657 Patients with Pure Ductal Carcinoma in Situ of the Breast: Correlation with Clinical, Histopathologic, Biologic Features, and Local Recurrence. Ann Surg Oncol. 2016 Feb; 23(2):482-9.
Score: 0.003
-
Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):102-10.
Score: 0.003
-
Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ? Ann Surg Oncol. 2015 Dec; 22(13):4270-9.
Score: 0.003
-
Molecular cytogenetic characterization of mammary neuroendocrine carcinoma. Hum Pathol. 2014 Sep; 45(9):1951-6.
Score: 0.002
-
Implementation of the american college of surgeons oncology group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy? Ann Surg Oncol. 2014 Aug; 21(8):2468-73.
Score: 0.002
-
Timing of infectious complications following breast-conserving therapy with catheter-based accelerated partial breast irradiation. Ann Surg Oncol. 2014 Aug; 21(8):2512-6.
Score: 0.002
-
Outcomes of sentinel lymph node dissection alone vs. axillary lymph node dissection in early stage invasive lobular carcinoma: a retrospective study of the surveillance, epidemiology and end results (SEER) database. PLoS One. 2014; 9(2):e89778.
Score: 0.002
-
Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013 Dec; 20(13):4103-12.
Score: 0.002
-
Therapeutic radiation dose delivered to the low axilla during whole breast radiation therapy in the prone position: implications for targeting the undissected axilla. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):116-122.
Score: 0.002
-
Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population. J Am Coll Surg. 2013 Jan; 216(1):105-13.
Score: 0.002
-
Changing behavior in clinical practice in response to the ACOSOG Z0011 trial: a survey of the American Society of Breast Surgeons. Ann Surg Oncol. 2012 Oct; 19(10):3152-8.
Score: 0.002
-
The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol. 2012 Oct; 19(10):3177-84.
Score: 0.002
-
Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol. 2012 Nov; 19(12):3777-84.
Score: 0.002
-
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41.
Score: 0.002
-
IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes. Exp Dermatol. 2010 Aug; 19(8):714-22.
Score: 0.002
-
Multicentric paragangliomas associated with Carney triad. Am Surg. 2010 Feb; 76(2):216-8.
Score: 0.002
-
A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg. 2009 May; 208(5):706-15; discussion 715-7.
Score: 0.002
-
Successful minimally invasive parathyroidectomy for primary hyperparathyroidism without using intraoperative parathyroid hormone assays. Am J Surg. 2006 Jan; 191(1):52-6.
Score: 0.001